NASDAQ:STOK

Stoke Therapeutics Q4 2025 Earnings Results & Report

Stoke Therapeutics logo
$26.63 -0.05 (-0.19%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$26.63 0.00 (0.00%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stoke Therapeutics reported Q4 2025 earnings on March 16, 2026. The company reported EPS of -$0.97, while revenue was $1.40 million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Stoke Therapeutics EPS Results

Actual EPS
-$0.97
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Stoke Therapeutics Revenue Results

Actual Revenue
$1.40 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Stoke Therapeutics Q4 2025 Earnings FAQ

Stoke Therapeutics (NASDAQ:STOK) reported earnings of -$0.97 per share for Q4 2025. The report was announced on Monday, March 16, 2026.

Stoke Therapeutics reported revenue of $1.40 million for Q4 2025.

Stoke Therapeutics Earnings Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Equities Analysts Issue Forecasts for STOK FY2026 Earnings
See More Stoke Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Stoke Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stoke Therapeutics and other key companies, straight to your email.

About Stoke Therapeutics

Stoke Therapeutics (NASDAQ:STOK) is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene. STK-001 is designed to restore productive SCN1A gene expression and increase production of functional sodium channel protein. The candidate has been evaluated in clinical studies involving children and adolescents with Dravet syndrome.

Founded in 2014 and headquartered in Bedford, Massachusetts, Stoke conducts research and development activities in the United States and works with clinical and research partners in support of its development programs. The company’s pipeline has also included additional investigational programs aimed at treating rare genetic diseases through targeted increases in gene expression.

View Stoke Therapeutics Profile